American International Group, Inc. Taysha Gene Therapies, Inc. Transaction History

American International Group, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.47 - $6.77 $27,772 - $76,121	-11,244 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$5.22 - $11.86 $4,129 - $9,381	-791 Reduced 6.57%	11,244 $73,000
Q4 2021 Feb 11, 2022	SELL	$11.43 - $19.2 $1,703 - $2,860	-149 Reduced 1.22%	12,035 $140,000
Q3 2021 Nov 12, 2021	SELL	$15.82 - $21.57 $4,587 - $6,255	-290 Reduced 2.32%	12,184 $227,000
Q2 2021 Aug 13, 2021	BUY	$19.29 - $26.38 $143,035 - $195,607	7,415 Added 146.57%	12,474 $264,000
Q1 2021 May 07, 2021	BUY	$20.3 - $31.75 $284 - $444	14 Added 0.28%	5,059 $103,000
Q4 2020 Feb 12, 2021	BUY	$19.14 - $28.13 $96,561 - $141,915	5,045 New	5,045 $134,000

107

136M

65.4K

41.7K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $100M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.